Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines

ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics raises $100M Series B financing to further develop “CRISPR by Design” platform and pipeline of breakthrough genetic medicines

Click to view original post